Barely Significant
← all excerpts

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.

Br J Cancer · 2021 · PMC8381132 · PMID 34426663

Europe PMCDOI
1
hedged sentence
0.0610
closest p · 1.2× alpha
0.0610
boldest claim

The sentences

a strong trendp = 0.061so close (0.05 < p ≤ 0.1)
The main benefit of olaparib was a strong trend in PFS2 (16.9 vs. 9.3 months, HR 0.66, 95% CI 0,43–1.02, p = 0.061), which is driven by long-term effects in the olaparib arm (rate of survival without progression after 36 months of 31.2% with olaparib vs. 13.1% for placebo).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.